Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) does about 2.82M shares in volume on a normal day but saw 2465121 shares change hands in the recent trading day. The company now has a market cap of 647.07M USD. Its current market price is $1.79, marking an increase of 2.87% compared to the previous close of $1.74. The 52 week high reached by this stock is $3.73 whilst the lowest price level in 52 weeks is $0.92.
Lexicon Pharmaceuticals Inc (LXRX) has a 20-day trading average at $1.6340 and the current price is -52.01% off the 52-week high compared with 94.57% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.6623 and its 200-day simple moving average is $1.8888. If we look at the stock’s price movements over the week, volatility stands at 5.27%, which increases to 5.30% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 61.49 to suggest the stock is neutral.
The consensus objective for the share price is $6.20, suggesting that the stock has a potential upside of 71.13% over the period.
FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on June 17, 2024 when H.C. Wainwright initiated the stock to “Buy” and issued a price target of $10. Jefferies initiated its price target at $3.
The current price level is 9.55%, 7.68%, and -5.23% away from its SMA20, SMA50, and SMA200 respectively, with the LXRX price moving below the 50-day SMA on current market day. Lexicon Pharmaceuticals Inc (LXRX) stock is up 6.55% over the week and 5.29% over the past month. Its price is 16.99% year-to-date and 72.12% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at -0.16 and -0.7 for whole year. Expected sales for next quarter are $5.63M, which analysts say will come at $11.32M for the current fiscal year and next year at $50.9M. In addition, estimates put the company’s current quarterly revenue at an average of $2.93M.
To reach the target analysts have set, the stock logically needs to grow 71.13 percent from here.
Outstanding shares total 361.49M with insiders holding 1.15% of the shares and institutional holders owning 79.25% of the company’s common stock. The company has a return on investment of -58.25% and return on equity of -94.10%. The beta has a value of 1.28. Price to book ratio is 2.70 and price to sales ratio is 177.77.
